20.500.12556/DiRROS-12417 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. non-small cell lung carcinoma - therapy drug therapy afatinib osimertinib GioTag study nedrobnocelični karcinom pljuč - terapija terapija z zdravili afatinib osimertinib raziskava GioTag true false true Future Medicine Ltd Angleški jezik Ni določen © 2019 Maximilian J Hochmair Neznano 2020-09-11 14:42:57 2020-09-11 14:42:57 2022-08-18 03:37:19 0000-00-00 00:00:00 2019 0 Velika Britanija 0 Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Tanja Cufer; Opis vira z dne 10. 1. 2020; str. 2905-2914 iss. 25 Vol. 15 Sep. 2019 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.2 1744-8301 10.2217/fon-2019-0346 2048610929 521824025 RAZ_Hochmair_Maximilian_J_i2019.pdf RAZ_Hochmair_Maximilian_J_i2019.pdf 1 AE826F62EC54CB83F71667FE803EEB71 f91534d1ad8755591965ae1d8e03359d21baedecbc49ede8d697d1f7f0fe4a48 8dbf29be-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17310 RAZ_Hochmair_Maximilian_J_i2019.pdf RAZ_Hochmair_Maximilian_J_i2019.pdf 1 501E9A968487DEB2D03082EAB847B278 bca5140497959095c0fa9c3ee0e3ecd2ad1510f5c5f645a30af4db24cd69bfa6 8dcd5ca5-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17311 https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=14975 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0